TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Nureca Limited
NURECA Updated about 18 hours ago

Nureca Limited Share Price

NSE closing price and which mutual funds hold this stock

TopFund Score: 43/100 · Weak See breakdown ↓

Daily NSE closing prices — this stock isn't in the live-tracked universe yet.

NSE Close — 25 Sep 2026

₹351.5

Change

+9.15 (2.67%)

Open

₹345.0

Prev. Close

₹342.35

Day High

₹354.6

Day Low

₹335.0

Volume Analysis

Traded

13,395

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Trading within 3% of its 52-week high (₹358.0)
  • •Promoter holding is rising

Weaknesses (3)

  • •Low return on equity (1.12%)
  • •Below-average fundamentals quality score (43/100)
  • •Low operating margin (2.7%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹378.66 ₹366.63 ₹359.06 ₹347.03 ₹339.46 ₹327.43 ₹319.86
Fibonacci ₹366.63 ₹359.14 ₹354.52 ₹347.03 ₹339.54 ₹334.92 ₹327.43
Camarilla ₹356.89 ₹355.09 ₹353.3 ₹347.03 ₹349.7 ₹347.91 ₹346.11

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+13.1%

1 Week

+3.75%

1 Month

+6.18%

3 Months

+48.06%

6 Months

+54.56%

1 Year

+53.94%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹96.28

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

2.11%

Net margin 2.61% × asset turnover 0.75x × equity multiplier 1.08x

Company Overview

Sector

Healthcare

Market Cap

₹335 Cr

P/E (TTM)

77.3

ROE

1.12%

Book Value

₹189.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.

TopFund Analysis

Nureca Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (100/100), while Liquidity (0/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹358.0); promoter holding is rising; low return on equity (1.12%); below-average fundamentals quality score (43/100).

TopFund Score — Fundamentals Quality

43/100 — Weak

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

16

Valuation

25

Cash Flow

15

Corporate Governance

66

Momentum

96

Institutional Ownership

30

Business Quality

28

Risk & Volatility

41

Liquidity

0

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of -7.19% over past five years.
  • −Company has a low return on equity of -0.56% over last 3 years.
  • −Earnings include an other income of Rs.7.35 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 ('PIT Regulations') 26 Sep

Nureca disclosed promoter Saurabh Goyal's share purchases under PIT Regulation 7(2); manual filing due to system issues.

Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 ('PIT Regulations') 25 Sep

Nureca disclosed promoter Saurabh Goyal share purchases on 10 September 2026 under PIT Regulations.

"Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 (PIT Regulations)'''' 10 Sep

Promoter group member Ms. Smita Goyal purchased Nureca shares; Form C disclosed under PIT Regulations on September 10, 2026.

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 10 Sep 10 Sep
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 10 Sep 10 Sep

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 21 31 22 17 20 31 26 32 34 38 40 35 40
Expenses + 24 30 27 21 23 34 30 31 35 34 36 41 37
Operating Profit -3 1 -4 -4 -2 -2 -4 1 -1 3 3 -6 3
OPM % -13.66% 4.4% -19.0% -26.1% -11.64% -7.53% -15.15% 3.78% -1.64% 8.66% 8.2% -16.32% 8.48%
Other Income + 3 3 6 -1 6 3 1 2 3 2 2 1 2
Interest 0 0 0 0 0 0 0 1 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 0 1
Profit before tax -1 4 1 -6 3 0 -3 2 1 5 5 -6 4
Tax % -23.66% 25.83% 82.11% -35.86% 36.64% 585.71% -13.85% -20.0% 34.15% 21.13% 19.96% 10.71% 30.93%
Net Profit + -1 3 0 -4 2 0 -3 2 1 4 4 -6 3
EPS in Rs -1 3 0 -4 2 0 -3 2 1 4 4 -6 3
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 62 99 213 256 111 92 110 147 153
Expenses + 53 90 152 200 126 102 117 147 149
Operating Profit 9 10 62 56 -15 -10 -8 0 4
OPM % 15.0% 10.0% 29.0% 22.0% -13.0% -11.0% -7.0% 0.1% 2.7%
Other Income + 0 0 3 8 7 11 12 8 7
Interest 0 1 2 1 0 0 1 1 1
Depreciation 0 0 0 1 2 2 2 2 2
Profit before tax 9 9 62 61 -11 -3 1 5 8
Tax % 30.0% 26.0% 26.0% 26.0% -23.0% -30.0% 37.0% 58.0% —
Net Profit + 6 6 46 45 -8 -2 1 2 4
EPS in Rs 6,230 6,400 46 45 -8 -2 1 2 4
Dividend Payout % 0.0% 0.0% 4.0% 7.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 8 15 153 193 185 183 184 171
Borrowings + 0 10 4 4 3 3 5 2
Other Liabilities + 15 9 19 12 8 10 11 13
Total Liabilities 24 34 186 219 207 205 210 196
Fixed Assets + 1 1 4 10 9 7 9 14
CWIP 0 0 0 0 0 0 0 0
Investments 0 0 0 33 59 94 1 1
Other Assets + 23 33 182 175 139 104 200 182
Total Assets 24 34 186 219 207 205 210 196
Equity Capital 0 0 10 10 10 10 10 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 0 -8 35 1 10 -3 -19 3
Cash from Investing Activity + 0 0 -110 -3 -16 18 8 14
Cash from Financing Activity + 0 8 92 -7 -2 -1 0 -20
Net Cash Flow 0 0 17 -9 -8 14 -11 -2
CFO/OP 4 -82 81 35 -96 39 234 1,464
Free Cash Flow 0 -8 34 -5 10 -4 -23 -3

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 63.24% → 68.09%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 36.67% 36.69% 36.69% 36.69% 35.53% 35.54% 34.59% 35.56% 34.92% 34.91% 31.39% 31.57%
Promoters 63.24% 63.24% 63.24% 63.24% 63.78% 64.06% 64.3% 64.33% 64.97% 64.97% 68.09% 68.09%
FII 0.1% 0.07% 0.07% 0.07% 0.69% 0.36% 1.07% 0.07% 0.07% 0.08% 0.28% 0.11%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.04% 0.04% 0.04% 0.04% 0.04% 0.24% 0.24%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Nureca Limited (this stock) 335 77.3 1.86 1.12%
Ambalal Sarabhai Ent L 316 22.2 2.0 12.4%
Lyka Labs Ltd. 310 — 3.31 -10.2%
Qms Medical Allied S Ltd 380 35.4 3.65 10.4%
Bilcare Ltd. 257 12.9 1.3 1.39%
Medicamen Biotech Limited 428 39.4 1.55 3.95%
Take Limited 229 38.9 7.38 16.5%

Which Mutual Funds Hold Nureca Limited?

Frequently Asked Questions about Nureca Limited

Community Sentiment

What are other investors saying about Nureca Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.